Translation and cross-cultural adaptation of the Get Active Questionnaire for Pregnancy (kwestionariusz “Badź Aktywna w Ciąży”) to support physical activity among pregnant women in Poland

Introduction: Physical activity during pregnancy is established to derive clinically meaningful improvements in pregnancy, childbirth, and postpartum health outcomes. Evidence-based pre-screening tools have been developed to support the implementation of physical activity programmes, and enhance communication between health care providers, exercise professionals and pregnant women. The Get Active Questionnaire for Pregnancy (GAQ-P) and the Health Care Provider Consultation Form for Prenatal Physical Activity (HCPCF) empower pregnant women to identify whether they require additional counselling from their obstetric health care provider in terms of physical activity. However, these tools are not available in Polish. This work details the process taken to translate the GAQ-P and HCPCF into Polish. Material and Methods: We followed the translation process outlined by the Translation and Cultural Adaptation International Society for Pharmacoeconomics and Outcomes Research (ISPOR) guidelines between August 2022 and August 2023. We formed an expert group that included representatives of the Polish Society of Sports Medicine, The Polish Society of Gynaecologists and Obstetricians, practitioners, and scientists in physical activity during pregnancy. We implemented 9 of the 10 steps recommended by ISOPR in the translation process. At the Cognitive Debriefing stage, we collected opinions on the Polish version of GAQ-P and HCPCF from 70 stakeholders on the clarity and cultural appropriateness of the translation. Results and Conclusions: Target users have positively evaluated the Polish version of GAQ-P and HCPCF. Thanks to the ISPOR methodology, we obtained a trustworthy, evidence-based screening tools, which can reduce the barriers for most women to be physically active during pregnancy

Titin Truncating Variants in Dilated Cardiomyopathy – Prevalence and Genotype-Phenotype Correlations

<div><p><i>TTN</i> gene truncating variants are common in dilated cardiomyopathy (DCM), although data on their clinical significance is still limited. We sought to examine the frequency of truncating variants in <i>TTN</i> in patients with DCM, including familial DCM (FDCM), and to look for genotype-phenotype correlations. Clinical cardiovascular data, family histories and blood samples were collected from 72 DCM probands, mean age of 34 years, 45.8% FDCM. DNA samples were examined by next generation sequencing (NGS) with a focus on the <i>TTN</i> gene. Truncating mutations were followed up by segregation study among family members. We identified 16 <i>TTN</i> truncating variants (<i>TTN</i> trunc) in 17 probands (23.6% of all cases, 30.3% of FDCM, 17.9% of sporadic DCM). During mean 63 months from diagnosis, there was no difference in adverse cardiac events between probands with and without TTN truncating mutations. Among relatives 29 mutation carriers were identified, nine were definitely affected (31%), eight probably affected (27.6%) one possibly affected (3.4%) and eleven were not affected (37.9%). When relatives with all affected statuses were combined, disease penetrance was still incomplete (62.1%) even after exclusion of unaffected relatives under 40 (82%) and was higher in males versus females. In all mutation carriers, during follow-up, 17.4% had major adverse cardiac events, and prognosis was significantly worse in men than in women. In conclusion, <i>TTN</i> truncating variants were observed in nearly one fourth of young DCM patient population, in vast majority without conduction system disease. Incomplete penetrance suggests possible influence of other genetic and/or environmental factors on the course of cardiotitinopathy. Counseling should take into account sex and incomplete penetrance.</p></div

Comparison of clinical data on <i>TTN</i> trunc positive versus <i>TTN</i> trunc negative DCM probands.

<p>Comparison of clinical data on <i>TTN</i> trunc positive versus <i>TTN</i> trunc negative DCM probands.</p

List of <i>TTN</i> truncating variants identified in the study group annotated to transcript NM_001267550.2.

<p>List of <i>TTN</i> truncating variants identified in the study group annotated to transcript NM_001267550.2.</p

Clinical characteristics of affected and not affected <i>TTN</i> trunc positive relatives.

<p>Clinical characteristics of affected and not affected <i>TTN</i> trunc positive relatives.</p

Kaplan-Meier cumulative survival curves for SAE (HF death, OHT or LVAD) in 46 carriers of <i>TTN</i> truncating variants, males and females, p = 0.018, log-rank test = -2.37.

<p>Kaplan-Meier cumulative survival curves for SAE (HF death, OHT or LVAD) in 46 carriers of <i>TTN</i> truncating variants, males and females, p = 0.018, log-rank test = -2.37.</p